Pharmaceutical
Fresenius increases – and wants to avert Trump -Zölle
The medical and clinic group is on the upper and wants to avoid threatening tariffs under Donald Trump. In talks with American authorities, Fresenius relies on his strong position in the USA.
The Clinic and Medicine Control Fresenius deserves more and relies on discussions with the US government to avert impending pharmaceuticals. Good results from the clinical daughter Helios and the Kabi medication division in the first quarter make CEO Michael Sen optimistic to achieve the annual goals despite possible tariffs under US President Donald Trump.
The US government has so far except for pharmaceutical imports from its huge customs package, but is currently running a review. “We are in dialogue with the local authorities,” said Sen. The DAX group could bring in the argument that Fresenius provides the American health system essential and cheap imitators (generics) and mostly produce on site, while in the United States there is a lack of pharmaceutical care.
The United States is a very important market in which Fresenius will continue to invest, said Sen. Currently, the group has achieved a good ten percent of its turnover through the generous daughter Kabi. Most of the medication sold in the United States – 70 percent – produces the daughter locally. Fresenius should therefore be less affected by import duties than the majority of the generic competition producing away from countries such as India and China.
In the first quarter, Fresenius grew unexpectedly. The sales, which was adjusted for special effects, rose by seven percent to 5.63 billion euros in the same period last year. The adjusted result before interest and tax grew by four percent to 654 million euros. The tailwind gave a savings program and the core business at Kabi with medicines, clinical nutrition and medical technology.
The bottom line was that the profit rose by 12 percent to 416 million euros across the group, which is excluded from participation in the dialysis specialist Fresenius Medical Care.
In 2025, Fresenius plans to increase sales away from special and currency effects by four to six percent. Well -known risks such as disadvantageous tariffs are taken into account, but only if they can currently be estimated.
dpa
Source: Stern
